HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2017
At a glance
- Drugs Tivanisiran (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms HELIX
- Sponsors Sylentis
- 01 Jun 2017 Status changed from not yet recruiting to recruiting, according to a PharmaMar media release.
- 25 May 2017 Planned initiation date changed from 4 May 2017 to 26 May 2017.
- 25 May 2017 Status changed from recruiting to not yet recruiting.